Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: FATE

Fate Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for FATE. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.05

Fate Therapeutics, Inc. (NASDAQ: FATE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 12:15 UTC.

What Fate Therapeutics, Inc. does

This is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using human induced pluripotent stem cells (iPSCs) engineered with synthetic controls to enhance cell function. The company creates clonal master iPSC lines that serve as renewable sources for manufacturing uniform T-cell and natural killer cell therapies designed to treat autoimmune diseases and certain cancers. The company operates a fully integrated manufacturing facility and has developed a proprietary iPSC platform supported by a significant intellectual property portfolio.

Summarized from Fate Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.05

Revenue, margins & earnings

FY2021: net loss $212M on revenue $56M$56MFY2021FY2022: net loss $282M on revenue $96M$96MFY2022FY2023: net loss $161M on revenue $64M$64MFY2023FY2024: net loss $186M on revenue $14M$14MFY2024FY2025: net loss $136M on revenue $7M$7MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-05
  • 2026-08-05See RemarksSale-38,800$95.4K
  • 2026-08-05President and CEOSale-43,947$108.1K
  • 2026-06-15DirectorStock Option (Right to Buy)Award87,900—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Fate Therapeutics, Inc. do?

This is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using human induced pluripotent stem cells (iPSCs) engineered with synthetic controls to enhance cell function.

When did FATE last file with the SEC?

Fate Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-15. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 12:15 UTC. This page is also available as JSON at /api/data?ticker=FATE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for FATE and 5,000+ tickers.

Create a free account — keep FATE
For your agent
GET /api/data?ticker=FATE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt